These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 23597930

  • 1. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
    Jiménez-Bonilla JF, Quirce R, Martínez-Rodríguez I, Banzo I, Rubio-Vassallo AS, Del Castillo-Matos R, Ortega-Nava F, Martínez-Amador N, Ibáñez-Bravo S, Carril JM.
    Lung Cancer; 2013 Jul; 81(1):71-6. PubMed ID: 23597930
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
    Tönnies S, Bauer TT, Misch D, Boch C, Blum T, Bittner RC, Förster GJ, Kollmeier J.
    Pneumologie; 2012 Apr; 66(4):212-7. PubMed ID: 22477481
    [Abstract] [Full Text] [Related]

  • 6. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB, Behrendt FF, Heinzel A, Krohn T, Mottaghy FM, Bauerschlag DO, Verburg FA.
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [Abstract] [Full Text] [Related]

  • 7. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

  • 8. Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers.
    Liu BJ, Dong JC, Xu CQ, Zuo CT, Le JJ, Guan YH, Zhao J, Wu JF, Duan XH, Cao YX.
    Chin Med J (Engl); 2009 Aug 05; 122(15):1749-54. PubMed ID: 19781319
    [Abstract] [Full Text] [Related]

  • 9. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, Mancini M, Ardissone F.
    Eur J Cardiothorac Surg; 2009 Sep 05; 36(3):440-5. PubMed ID: 19464906
    [Abstract] [Full Text] [Related]

  • 10. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun 05; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 11. Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients.
    Takenaka D, Ohno Y, Koyama H, Nogami M, Onishi Y, Matsumoto K, Matsumoto S, Yoshikawa T, Sugimura K.
    Eur J Radiol; 2010 Jun 05; 74(3):458-64. PubMed ID: 19398291
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE, Diaz R, McElmurray J, Csiki I, Duggan D, Lu B, Delbeke D.
    Clin Nucl Med; 2010 Apr 05; 35(4):237-43. PubMed ID: 20305410
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
    Hamidian Jahromi A, Sangster G, Zibari G, Martin B, Chu Q, Takalkar A, Shi R, Shokouh-Amiri H.
    JOP; 2013 Jul 11; 14(4):466-8. PubMed ID: 23846950
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B, Schwenzer NF, Gatidis S, Koenigsrainer I, Koenigsrainer A, Beckert S, Mueller M, Claussen CD, Pfannenberg C.
    Rofo; 2014 Apr 11; 186(4):359-66. PubMed ID: 24683168
    [Abstract] [Full Text] [Related]

  • 19. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
    Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, Ohbayashi C, Sugimura K.
    J Magn Reson Imaging; 2007 Oct 11; 26(4):1071-80. PubMed ID: 17896365
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.